Fennec Pharma Files 8-K on Other Events and Financial Exhibits

TL;DR

**Fennec Pharma just dropped an 8-K on Feb 29, 2024, for 'Other Events' and 'Financial Statements and Exhibits' – keep an eye out for details!**

AI Summary

FENNEC PHARMACEUTICALS INC. filed an 8-K on February 29, 2024, reporting 'Other Events' and 'Financial Statements and Exhibits'. The filing indicates a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, with the earliest event reported also on February 29, 2024. The company, incorporated in British Columbia, Canada, has a Commission File Number of 001-32295 and is based in Research Triangle Park, NC.

Why It Matters

This filing signals that Fennec Pharmaceuticals has new information regarding its operations or financial status, which could impact investor perception and future stock performance.

Risk Assessment

Risk Level: low — The 8-K filing itself is a standard disclosure and does not inherently indicate high risk without further details on the 'Other Events' or 'Financial Statements and Exhibits'.

Key Players & Entities

• FENNEC PHARMACEUTICALS INC. (company) — Registrant
• February 29, 2024 (date) — Date of earliest event reported and filing date
• 001-32295 (string) — Commission File Number
• British Columbia, Canada (string) — Jurisdiction of incorporation
• Research Triangle Park, NC (string) — Business address location

FAQ

Filing Documents

• tm247601d1_8k.htm (8-K) — 25KB
• tm247601d1_ex99-1.htm (EX-99.1) — 14KB
• tm247601d1_ex99-1img01.jpg (GRAPHIC) — 6KB
• 0001104659-24-029355.txt ( ) — 221KB
• fencf-20240229.xsd (EX-101.SCH) — 3KB
• fencf-20240229_lab.xml (EX-101.LAB) — 33KB
• fencf-20240229_pre.xml (EX-101.PRE) — 22KB
• tm247601d1_8k_htm.xml (XML) — 4KB

01

Item 8.01. Other Events. On February 29, 2024, Fennec Pharmaceuticals Inc. issued a news release announcing preliminary unaudited information and management estimates for the fourth quarter 2023. Results are subject to the completion of Fennec's financial closing procedures and year-end audit. A copy of the news release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Current Report on Form 8-K, including the exhibit attached hereto, is being furnished and shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), or incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, unless such subsequent filing specifically references this Form 8-K.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description Exhibit 99.1 Press Release dated February 29, 2024 Exhibit 104 Cover Page Interactive Data File (formatted in Inline XBRL) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FENNEC PHARMACEUTICALS INC. Date February 29, 2024 By: /s/ Robert Andrade Robert Andrade Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR